Cannabis and Opioid Use Disorder, Study 2

Phase 1Not Yet RecruitingNCT07661446

University of Kentucky100 enrolled

Overview

This inpatient study enrolls healthy individuals who have opioid use disorder. Participants live at the University of Kentucky Hospital for approx. 6 weeks. During this time, we will examine how repeated doses of oral cannabis and acute doses of oral and inhaled cannabis 1) modify the intensity and time course of opioid withdrawal, 2) modify the effects of intranasal opioid administration and 3) impact the safety of opioid administration.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

TRIPLE

Enrollment

100

Conditions

Opioid Use Disorders Cannabis Use

Interventions

Inhaled CannabisDRUG

Participants will receive inhaled cannabis and placebo

Intranasal OpioidDRUG

Participants will receive intranasal opioids and placebo

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants with moderate to severe opioid use disorder Exclusion Criteria: * Individuals who do not use opioids or do not experience opioid withdrawal when they stop using opioids

Locations (1)

University of Kentucky

Lexington, Kentucky, United States

Outcomes

Primary Outcomes

Opioid withdrawal severity

Opioid severity is a participant-rated outcome that will be measured on a visual analog scale (0-100)

Time frame: This outcome will be assessed regularly from baseline through 6 hours post cannabis dose during experimental sessions.

Central Contacts

Paul Nuzzo

CONTACT

859-323-0002 paul.nuzzo@uky.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.